BioArctic

BioArctic EBIT per Share

The EBIT per Share of BioArctic (BIOA B.ST) as of Sep 26, 2026 is 15.50 SEK. In the previous year, EBIT per Share was -2.59 SEK — a change of -699.40% (higher).

EBIT per Share

15.50SEK

YoY

-699.40%

Last updated:

EBIT per Share of BioArctic is 2026 15.50 SEK. EBIT per Share of BioArctic was 2025 -2.59 SEK. It decreases by -699.40% higher compared to the previous year.

The BioArctic EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2022
-0.12 SEK
Jan 1, 2023
2.86 SEK
Jan 1, 2024
-2.59 SEK
Jan 1, 2025
15.50 SEK
Jan 1, 2026 (e)
3.72 SEK
Jan 1, 2027 (e)
9.27 SEK
Jan 1, 2028 (e)
17.04 SEK
Jan 1, 2029 (e)
29.50 SEK
The BioArctic EBIT per Share history
YEAREBIT per ShareYoY
est29.50SEK+73.14%
est17.04SEK+83.76%
est9.27SEK+149.54%
est3.72SEK-76.03%
15.50SEK-699.40%
-2.59SEK-190.37%
2.86SEK-2,580.92%
-0.12SEK-91.11%
-1.30SEK+33.40%
-0.97SEK-175.43%
1.29SEK-76.35%
5.45SEK+2,314.17%
0.23SEK-73.37%
0.85SEK+1,452.32%
0.05SEK—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

EBIT per Share of BioArctic is 15.50 SEK in 2026.

EBIT per Share of BioArctic changed from -2.59 SEK to 15.50 SEK, representing a -699.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — BioArctic

All Key Metrics — BioArctic